Aligos Therapeutics vs Ocugen
ALGS and OCGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALGS and OCGN compare
Ocugen is the larger company, worth 12 times as much as Aligos Therapeutics ($326M against $27.0M).
Aligos Therapeutics scores higher on the StockData Score (7 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALGS | OCGN |
|---|---|---|
| Size and price | ||
| Market cap | $27.0M | $326M |
| Share price | $2.16 | $0.960 |
| Change, 1 year | −68.6% | −28.9% |
| Change, 5 years | −99.5% | −87.6% |
| Beta (5Y) | 1.51 | 1.68 |
| Employees | 82 | 116 |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.6× | – |
| P/B | 2.4× | – |
| FCF yield | – | −19.6% |
| Fair value | $2.40 | – |
| Margin of safety | 9.8% | – |
| Growth | ||
| Revenue growth (TTM) | 122% | – |
| Revenue growth, 5Y average | – | 152% |
| Profitability | ||
| Operating margin | −1244% | – |
| Net margin | −1137% | – |
| Return on equity | −159% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −6.8× |
| Current ratio | 1.77 (better) | 0.77 |
| Altman Z-score | −24.54 | −6.76 (better) |
| Piotroski F-score | 4 (better) | 0 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 18.4% | 42.8% |
| Held by insiders | – | 2.4% |
| Insider net buying, 12 months | – | −$1.1M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 32.5% |
Go deeper
- ALGS stock overview
- ALGS income statement
- ALGS valuation and score
- OCGN stock overview
- OCGN income statement
- OCGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.